Skip to main content
Top
Published in: Breast Cancer Research and Treatment 1/2016

01-02-2016 | Erratum

Erratum to: JMJD2A-dependent silencing of Sp1 in advanced breast cancer promotes metastasis by downregulation of DIRAS3

Authors: Liliang Li, Pan Gao, Yuhua Li, Yiwen Shen, Jianhui Xie, Daming Sun, Aimin Xue, Ziqin Zhao, Zude Xu, Mingchang Zhang, Beixu Li, Jieqing Jiang

Published in: Breast Cancer Research and Treatment | Issue 1/2016

Login to get access

Excerpt

In the original publication of the article, the Fig. 5 was published erroneously with mislabeling of the downregulating protein and duplication of an image in Fig. 5e. The corrected Fig. 5 shown below is the correct representation of the data from this study. The authors apologize for this error.
Metadata
Title
Erratum to: JMJD2A-dependent silencing of Sp1 in advanced breast cancer promotes metastasis by downregulation of DIRAS3
Authors
Liliang Li
Pan Gao
Yuhua Li
Yiwen Shen
Jianhui Xie
Daming Sun
Aimin Xue
Ziqin Zhao
Zude Xu
Mingchang Zhang
Beixu Li
Jieqing Jiang
Publication date
01-02-2016
Publisher
Springer US
Published in
Breast Cancer Research and Treatment / Issue 1/2016
Print ISSN: 0167-6806
Electronic ISSN: 1573-7217
DOI
https://doi.org/10.1007/s10549-016-3714-2

Other articles of this Issue 1/2016

Breast Cancer Research and Treatment 1/2016 Go to the issue
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine